Journals / Klinik Psikofarmakoloji Bülteni / 2008 / Cilt: 18 - Sayı: 4

Şizofrenide artmış plazma seruloplazmin düzeyleri

Increased plasma ceruloplasmin levels in schizophrenia

Pages
282–287
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Plasma ceruloplasmin levels of schizophrenic patients were significantly higher than the healthy controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Ceruloplasmin is a protein in the human serum that is synthesized by hepatocytes, but extrahepatic gene expression in the brain, lung, spleen, and testis has also been reported.
📊
Key Findings & Data:Ceruloplasmin contains approximately 95% of serum copper and it carries copper from liver to numerous tissues.
💡
Conclusion & Impact:Results: Plasma ceruloplasmin levels of schizophrenic patients were significantly higher than the healthy controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Ceruloplasmin is a protein in the human serum that is synthesized by hepatocytes, but extrahepatic gene expression in the brain, lung, spleen, and testis has also been reported. Ceruloplasmin contains approximately 95% of serum copper and it carries copper from liver to numerous tissues. Ceruloplasmin level reşects largely the copper concentration of the serum. However, ceruloplasmin has also an antioxidant function that is known as the acute phase reactant. Additionally, ceruloplasmin has a role in the oxidation of serotonin, epinephrine, and norepinephrine. Abnormalities in ceruloplasmin levels have been associated with several neurodegenerative diseases. Moreover, the alteration of plasma ceruloplasmin levels has been linked to schizophrenia and its some clinical characteristics including acute or chronic phase, the length of the disease or whether the patients on treatment or not. However, there exists a controversy on relationship between the plasma level of ceruloplasmin and schizophrenia. There are number of reports on the increased or decreased and/or normal level of plasma ceruloplasmin in association with schizophrenia. These differences may have been originated from the usage of different measurement methods, clinical situations, and ethnobiological differences. In the present study, we aimed to investigate the association between plasma ceruloplasmin level and schizophrenia in Turkish patients. Methods: 60 patients (36 women and 24 men, mean of age 31.93±9.37 years, range 19-55) that were diagnosed as schizophrenia according to DSM-IV were included for this study at the Psychotic Disorders Unit, Department of Psychiatry, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey. The control group consisted of 40 healthy subjects in similar age and gender (23 women, 17 men). Venous blood samples were collected from the left forearm into heparinized tubes. The blood samples were centrifuged and the plasma was removed. Erel’s ceruloplasmin measurement method that is based on the enzymatic oxidation of ferrous ions to ferric ions was used. SPSS Windows program 13.0 was applied for statistical analysis. Results: Plasma ceruloplasmin levels of schizophrenic patients were significantly higher than the healthy controls (p

Özet

Amaç: Seruloplazmin hepatositler tarafından sentezlenen insan serumunda bulunan bir proteindir. Ayrıca karaciğer dışında beyin, akciğer, dalak ve testis gibi organlarda da gen ekspresyonları gösterilmiştir. Seruloplazmin serum bakırının yaklaşık %95’ini içerir ve bakırı diğer birçok dokuya taşır. Seruloplazmin büyük oranda bakır yoğunluğunu yansıtır. Seruloplazmin aynı zamanda antioksidan etkiye sahiptir ve bir akut faz reaktanıdır. Ayrıca, seruloplazmin serotonin, epinefrin ve norepinefrinin oksidasyonunda da rol almaktadır. Seruloplazmin anormalliği birçok nörodejeneratif hastalıkla ilişkilendirilmiştir. Seruloplazminin şizofreni ve hastanın akut veya kronik fazda olması, hastalık süresi, hastanın tedavide olup olmaması gibi şizofreninin bazı klinik özellikleriyle de bağlantılı olduğu bildirilmiştir. Bununla beraber, seruloplazmin ve şizofreni ilişkisi hakkında hala çelişkiler vardır, çünkü şizofrenide seruloplazmin düzeyinin arttığı, azaldığı ve normal sınırlarda kaldığı ile ilgili yayınlar da bulunmaktadır. Bu çelişki, kullanılan ölçüm yönteminin farklılığından, hastaların klinik durumunun farklı olmasından ve etnobiyolojik farklılıklardan kaynaklanabilir. Biz bu çalışmada Türk hastalarda plazma seruloplazmin düzeyi ile şizofreni ilişkisini araştırmayı amaçladık. Yöntem: Çalışmaya Gaziantep Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Psikotik Bozukluklar Birimi’nde ayaktan takip edilen 116 hasta içinden DSM-IV’e göre şizofreni tanısı konulmuş ve dışlama ölçütlerini karşılamayan 60 hasta (24 erkek, 36 kadın, yaş ortalaması 31.93±9.37 yıl, yaş aralığı 19–55 yıl) alındı. Yaş ve cinsiyet olarak benzer 40 sağlıklı kişiden (17 erkek, 23 kadın, yaş ortalaması 35.53±9.86 yıl, yaş aralığı 20–58) kontrol grubu oluşturuldu. Heparinize tüplere sol ön koldan venöz kan örnekleri alındı. Kan örnekleri santrifüj edilerek plazma ayrıldı. Ferröz iyonun ferik iyona enzimatik oksidasyonu temeline dayanan Erel’in seruloplazmin ölçüm yöntemi ile seruloplazmin ölçümü yapıldı. Bulgular: Seruloplazmin düzeyi şizofreni hastalarında sağlıklı kontrollere göre anlamlı olarak yüksekti (p

🔖

Cite This Article

BULUT, M., EREL, Ö., SAVAŞ, H. A., SELEK, S., HERKEB, H., ALTINDAĞ, A., VİRİT, O., YUMRU, M. (2022). Şizofrenide artmış plazma seruloplazmin düzeyleri. Klinik Psikofarmakoloji Bülteni, Cilt: 18 - Sayı: 4, 282–287. https://ajindex.com/articles/574344

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 2005
  2. 640 2. Abood LG, Gibbs FA, Gibbs E. Comparative study of blood ceruloplasmin in schizophrenia and other disorders. AMA Arch Neurol Psychiatr 1957
  3. 643–645 3. Puzynski S, Kalinowski A. Investigations of some physiobiochemical properties of ceruloplasmin in schizophrenics and in normal subjects. Nature 1966
  4. 400 4. Puzynski S. Investigations on ceruloplasmin in chronic schizophrenia. Pol Med J 1966
  5. 1491 5. Alias AG, Vijayan N, Nair DS, Sukumaran M. Serum ceruloplasmin in schizophrenia: significant increase in acute cases especially in catatonia. Biol Psychiatry 1972
  6. 238 6. Giner J, Morell M, Osorio C. Serum levels of ceruloplasmin as an index of the clinical evolution in schizophrenic patients. Rev Esp Fisiol 1972
  7. 42 7. Chugh T, Dhingra R, Gulati R, Bathla J. Copper metabolism in schizophrenia. Indian J Med Res 1973
  8. 1152 8. Domino EF, Krause RR, Thiessen MM, Batsakis JG. Blood protein fraction comparisons of normal and schizophrenic patients. Arch Gen Psychiatry 1975
  9. Rahman B, Rahman MA, Hassan Z. Variation of copper and ceruloplasmin levels with liver function tests in schizophrenic patients. Biomedicine 1978
  10. 241 10. Bock E, Weeke B, Rafaelsen OJ. Serum proteins in acutely psychotic patients. J Psychiatr Res 1971
  11. 9 11. Seal US, Eist H. Elevation of serum protein-bound carbohydrates and haptoglobin in schizophrenia. Clin Chem 1966
  12. 716 12. Morera AL, Henry M, García-Hernández A, Fernández-López L. Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Actas Esp Psiquiatr 2007
  13. 252 13. Wolf TL, Kotun J, Meador-Woodruff JH. Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia. Schizophr Res 2006
  14. 171 14. Gaffney D, Fell GS, O’Reilly DS. ACP Best Practice No 163. Wilson’s disease: acute and presymptomatic laboratory diagnosis and monitoring. J Clin Pathol 2000
  15. 807–812 15. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Relationship between serum copper, ceruloplasmin, and nonceruloplasmin- bound copper in routine clinical practice. Clin Chem 2005
  16. 1559 16. Bowman MB, Lewis M. The copper hypothesis of schizophrenia: a review. Neurosci Biobehav Rev 1982
  17. 328 17. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR,